SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The special case of gene therapy pricing
1 references·8 citing·27 second hop
The special case of gene therapy pricing (2014)The special case of gene therapy pricingInnovation Policy and the Economy (2007)Innovation Policy and the Eco…Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions (2020)Market access of gene therapi…Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies (2020)Barriers and Opportunities fo…Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis (2020)Application of Managed Entry …A Hybrid MCDM Model for Evaluating Strategic Alliance Partners in the Green Biopharmaceutical Industry (2019)A Hybrid MCDM Model for Evalu…Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures (2018)Affordability Challenges to V…Funding breakthrough therapies: A systematic review and recommendation (2017)Funding breakthrough therapie…Gene Therapies: The Challenge of sUper-High-Cost Treatments and How to Pay for them (2016)Gene Therapies: The Challenge…Glybera's Second Act: The Curtain Rises on the High Cost of Therapy (2015)Glybera's Second Act: The Cur…Pricing and reimbursement of orphan drugs: the need for more transparency (2011)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework (2014)Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’ (2006)What principles should govern the use of managed entry agreements? (2011)Advanced therapy medicinal products: current and future perspectives (2016)Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement (2013)Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2013)Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage (2017)Value-based pricing for advanced therapy medicinal products: emerging affordability solutions (2021)Fuzzy sets (1965)Fuzzy sets (1996)Best-worst multi-criteria decision-making method (2014)A Hybrid Multi-Criteria Decision-Making Model Combining DANP with VIKOR for Sustainable Supplier Selection in Electronics Industry (2023)Assessment of barriers to IoT-enabled circular economy using an extended decision- making-based FMEA model under uncertain environment (2023)International strategic alliances for collaborative product Innovation: An agent-based scenario analysis in biopharmaceutical industry (2023)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration (2009)The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)Overcoming Challenges Facing Advanced Therapies in the EU Market (2016)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force (2013)Use of content analysis to conduct knowledge-building and theory-generating qualitative systematic reviews (2013)Assessing the impact of organizational practices on the relative productivity of university technology transfer offices: an exploratory study (2002)Do Scientists Pay to Be Scientists? (2004)A tale of two market failures: Technology and environmental policy (2005)
this work references cited by second hop

References

  • 2007Innovation Policy and the Economy462 cited

Cited by

  • 2018Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures65 cited
  • 2016Gene Therapies: The Challenge of sUper-High-Cost Treatments and How to Pay for them58 cited
  • 2020Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions53 cited
  • 2020Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies53 cited
  • 2017Funding breakthrough therapies: A systematic review and recommendation52 cited
  • 2020Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis48 cited
  • 2015Glybera's Second Act: The Curtain Rises on the High Cost of Therapy48 cited
  • 2019A Hybrid MCDM Model for Evaluating Strategic Alliance Partners in the Green Biopharmaceutical Industry39 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work